The Antibody Drug Conjugates market will definitely witness an increase in the partnership and collaborative agreements to develop these drugs. It has been observed that the process of drug development is highly correlated to basic research in Biology and Medicine. Specifically, the details about target molecules and their functions along with their involvement in pathology generally stem from basic research which is conducted in universities and public research institutes. The recent years have thus witnessed a growing relationship between the pharma companies and the academic institutions. Majority of the pharmaceutical companies across the globe have been reducing the size of their departments for basic research. Instead they have started to depend heavily on venture companies and universities, which act as the major source of knowledge. “Antibody Drug Conjugate Market Opportunity Analysis” Report Highlights: Global ADC Market Insight ADC Patent Analysis Orphan Status & ADC Favorable Market Drivers & Key Issues to be Discussed ADC Clinical Trial Insight by Phase & Target Indications ADC Profiles in Report: 201 Majority of ADC in Preclinical Phase: 83 Marketed ADC Clinical Profiles

1. Antibodies Emerging As Viable Treatment for Cancers
Antibody Drug Conjugate Market & Clinical Pipeline Assessed by KuicK Research
“Antibody Drug Conjugate Market Opportunity Analysis” Report Highlights:
 Global ADC Market Insight
 ADC Patent Analysis
 Orphan Status & ADC
 Favorable Market Drivers & Key Issues to be Discussed
 ADC Clinical Trial Insight by Phase & Target Indications
 ADC Profiles in Report: 201
 Majority of ADC in Preclinical Phase: 83
 Marketed ADC Clinical Profiles
There is an advantage in using ADCs over chemotherapy because of the very design of these
ADCs. They have been designed in such a way that they have the potential to kill the cell
activities of small molecules and the pharmacokinetic and biodistribution properties of
monoclonal antibodies. The ADCs help in enhancing the antibodies by chemically conjugating
a cytotoxic payload which could be delivered and released at the tumor while simultaneously
limiting the systemic exposure to the cytotoxic agent.
The traditional treatment of chemotherapy involves the use of small molecules which have
the capability to destroy or kill the dividing cells. This is generally achieved through
antimitotic or DNA-damaging mechanisms. However, a major disadvantage of this treatment
method is that the controlled administration of these drugs, in most cases, results in
damaging of the healthy tissues also in the human body. Thus the patient undergoing
chemotherapy, suffers from a major loss of overall immunity, which poses other significant
issues. Balancing these two activities (i.e. killing the tumor cells and simultaneously leaving
the healthy tissues untouched) has not been successful and has led to a lack of efficiency and
tolerability of single-agent chemotherapy.
For Report Sample Contact: avinash@kuickresearch.com